Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28039072 | 0.84 | ALDH1A1 (0.51) | TSHRCTSSKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2642487 | 0.83 | ALDH1A1 (0.40) | TSHRCTSSKMT2ACXCR2ALDH1A1 | |
| SCHEMBL2642491 | 0.81 | COMT (0.45) | TSHRCTSSCXCR2ALDH1A1L3MBTL1 | |
| SCHEMBL1248188 | 0.74 | AKR1B1 (0.56) | TSHRMCOLN3LMNAKMT2APTGES2 | |
| SCHEMBL2105627 | 0.74 | CTSS (0.40) | TSHRCTSSMCOLN3CHRM1 | |
| SCHEMBL4031272 | 0.73 | ALDH1A1 (0.66) | TSHRMCOLN3LMNAKMT2APTGES2 | |
| SCHEMBL3223437 | 0.73 | HTR6 (0.47) | CTSSCXCR2ALDH1A1L3MBTL1AKR1B1 | |
| SCHEMBL29519135 | 0.73 | TSHR (0.53) | TSHRMCOLN3LMNAKMT2APTGES2 | |
| SCHEMBL5607122 | 0.73 | TSHR (0.53) | TSHRMCOLN3LMNAKMT2APTGES2 | |
| SCHEMBL18457 | 0.73 | TSHR (0.53) | TSHRMCOLN3LMNAKMT2APTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | TSHR 2323/4885CTSS 2637/4885MCOLN3 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.